DeepMed Research

ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Phase 3

Not yet recruiting

Conditions: Geographic Atrophy
Age-Related Macular Degeneration

Interventions: Drug: avacincaptad pegol

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 20

Registration Number: NCT06970665

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ASP4396

First Posted Date: 2024-04-15

Last Posted Date: 2025-05-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 175

Registration Number: NCT06364696

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

and more 4 locations

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

Phase 3

Recruiting

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Placebo

First Posted Date: 2024-01-16

Last Posted Date: 2025-04-23

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 390

Registration Number: NCT06206408

Locations: 🇯🇵
Social Medical Corporation Caress Sapporo Caress Memorial Hospital, Sapporo-Shi, Hokkaido, Japan
🇯🇵
GyNet Medical Corporation Minamimorimachi Ladies' Clinic, Osaka-shi, Osaka, Japan
🇯🇵
Kitahorie Kanade Ladies Clinic, Osaka-shi, Osaka, Japan

and more 61 locations

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Phase 3

Active, not recruiting

Conditions: Hot Flashes

Interventions: Drug: Placebo
Drug: Fezolinetant

First Posted Date: 2024-01-16

Last Posted Date: 2025-04-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 277

Registration Number: NCT06206421

Locations: 🇯🇵
Daido Clinic, Nagoya-shi, Aichi, Japan
🇯🇵
Kotoni Ladies Clinic, Sapporo-shi, Hokkaido, Japan
🇯🇵
Juno Vesta Clinic hatta, Matsudo-shi, Chiba, Japan

and more 21 locations

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Phase 2

Terminated

Conditions: Melanoma
Sentinel Lymph Node Biopsy
Breast Cancer

Interventions: Drug: pudexacianinium chloride

First Posted Date: 2022-07-14

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1

Registration Number: NCT05457842

Locations: 🇺🇸
UCI Irvine Health-Chao Family Comprehensive Cancer Center Cancer, Orange, California, United States

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ASP3082
Drug: Cetuximab
Drug: Leucovorin
Drug: Nanoparticle albumin-bound-paclitaxel
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Oxaplatin
Drug: Gemcitabine
Drug: Cisplatin
Drug: Fluorouracil
Drug: Carboplatin
Drug: Irinotecan
Drug: Pemetrexed

First Posted Date: 2022-05-19

Last Posted Date: 2025-05-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 651

Registration Number: NCT05382559

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan

and more 42 locations

A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Phase 2

Completed

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Placebo

First Posted Date: 2021-09-05

Last Posted Date: 2024-10-26

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 147

Registration Number: NCT05034042

Locations: 🇯🇵
Sapporo Medical Center, NTT East Corporation, Sapporo-shi, Hokkaido, Japan
🇯🇵
Yoshinaga Women's Clinic, Kagoshima-shi, Kagoshima, Japan
🇯🇵
Tonan Hospital, Sapporo-shi, Hokkaido, Japan

and more 37 locations

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Pudexacianinium chloride
Drug: Placebo

First Posted Date: 2021-05-07

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 12

Registration Number: NCT04878471

Locations: 🇯🇵
JP81001, Sumida-ku, Tokyo, Japan

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

Phase 2

Terminated

Conditions: Primary Mitochondrial Myopathy

Interventions: Drug: Placebo
Drug: Bocidelpar

First Posted Date: 2020-11-24

Last Posted Date: 2024-10-30

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 34

Registration Number: NCT04641962

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

and more 8 locations

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Active, not recruiting

Conditions: Renal Anemia

Interventions: Drug: Roxadustat

First Posted Date: 2020-05-29

Last Posted Date: 2025-04-24

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 2104

Registration Number: NCT04408820

Locations: 🇯🇵
Site JP00023, Aichi, Japan
🇯🇵
Site JP00018, Fukui, Japan
🇯🇵
Site JP00021, Gifu, Japan

and more 44 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy